NO983991L - Serin-protease-inhibitorer - Google Patents

Serin-protease-inhibitorer

Info

Publication number
NO983991L
NO983991L NO983991A NO983991A NO983991L NO 983991 L NO983991 L NO 983991L NO 983991 A NO983991 A NO 983991A NO 983991 A NO983991 A NO 983991A NO 983991 L NO983991 L NO 983991L
Authority
NO
Norway
Prior art keywords
protease inhibitors
serine protease
thrombin
prodrug
prevention
Prior art date
Application number
NO983991A
Other languages
English (en)
Norwegian (no)
Other versions
NO983991D0 (no
Inventor
Anton Egbert Peter Adang
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO983991D0 publication Critical patent/NO983991D0/no
Publication of NO983991L publication Critical patent/NO983991L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06104Dipeptides with the first amino acid being acidic
    • C07K5/06113Asp- or Asn-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO983991A 1996-03-01 1998-08-31 Serin-protease-inhibitorer NO983991L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96200543 1996-03-01
PCT/EP1997/000938 WO1997031937A1 (en) 1996-03-01 1997-02-26 Serine protease inhibitors

Publications (2)

Publication Number Publication Date
NO983991D0 NO983991D0 (no) 1998-08-31
NO983991L true NO983991L (no) 1998-10-30

Family

ID=8223736

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983991A NO983991L (no) 1996-03-01 1998-08-31 Serin-protease-inhibitorer

Country Status (25)

Country Link
US (1) US6410684B1 (cs)
EP (1) EP0886647B1 (cs)
JP (1) JP2000506837A (cs)
KR (1) KR19990087415A (cs)
CN (1) CN1212704A (cs)
AR (1) AR006310A1 (cs)
AT (1) ATE221080T1 (cs)
AU (1) AU709330B2 (cs)
BR (1) BR9707808A (cs)
CA (1) CA2246246A1 (cs)
CZ (1) CZ277898A3 (cs)
DE (1) DE69714222T2 (cs)
DK (1) DK0886647T3 (cs)
ES (1) ES2180933T3 (cs)
HU (1) HUP9900390A3 (cs)
IL (1) IL120310A (cs)
NO (1) NO983991L (cs)
NZ (1) NZ331484A (cs)
PL (1) PL328875A1 (cs)
PT (1) PT886647E (cs)
RU (1) RU2178419C2 (cs)
TR (1) TR199801704T2 (cs)
TW (1) TW442452B (cs)
WO (1) WO1997031937A1 (cs)
ZA (1) ZA971667B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990082424A (ko) * 1996-02-13 1999-11-25 이.에이치. 리링크 세린 프로테아제 억제제
JP2001525823A (ja) 1997-05-15 2001-12-11 イーライ・リリー・アンド・カンパニー 抗血栓化合物
EA003856B1 (ru) 1998-04-30 2003-10-30 Агурон Фармасьютикалз, Инк. Антипикорнавирусные композиции, их получение и применение
WO2000009542A1 (en) * 1998-08-17 2000-02-24 Cortech, Inc. SERINE PROTEASE INHIBITORS COMPRISING α-KETO HETEROCYCLES
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
US7704958B1 (en) 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
DK1206484T3 (da) 1999-08-04 2005-01-24 Agouron Pharma Antipicornavirale forbindelser og sammensætninger, deres farmaceutiske anvendelser og materialer til deres syntese
AU2001266924A1 (en) 2000-06-14 2001-12-24 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
KR100904788B1 (ko) 2000-07-21 2009-06-25 쉐링 코포레이션 C형 간염 바이러스의 ns3-세린 프로테아제억제제로서의 신규한 펩티드
NZ523781A (en) * 2000-07-21 2004-10-29 Corvas Int Inc Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1358178A2 (en) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
JP2007527904A (ja) 2004-03-08 2007-10-04 プロシディオン・リミテッド グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−2−カルボン酸ヒドラジド化合物
JP2008521873A (ja) 2004-12-02 2008-06-26 プロシディオン・リミテッド ピロロピリジン−2−カルボン酸アミド類
JP5740308B2 (ja) * 2008-10-15 2015-06-24 ダニスコ・ユーエス・インク 修飾変異ボウマンブリックプロテアーゼインヒビター
FI3472149T3 (fi) 2016-06-21 2023-11-09 Orion Ophthalmology LLC Heterosyklisiä prolinamidijohdannaisia
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556655A (en) * 1984-09-24 1985-12-03 Schering Corporation Antihypertensive compounds having both diuretic and angiotensin converting enzyme inhibitory activity
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
ZW11290A1 (en) * 1989-07-14 1990-10-31 Smithkline Beecham Corp Hemoregulatory peptides
DE69431718T2 (de) * 1993-04-30 2003-07-10 Merck & Co., Inc. Thrombin-inhibitoren
US5672582A (en) * 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
ZA951618B (en) 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
WO1995035311A1 (en) 1994-06-17 1995-12-28 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
JPH0820597A (ja) * 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
CA2208772A1 (en) 1994-12-22 1996-06-27 Benoit Bachand Low molecular weight bicyclic thrombin inhibitors

Also Published As

Publication number Publication date
ES2180933T3 (es) 2003-02-16
DE69714222T2 (de) 2003-02-20
AU1877597A (en) 1997-09-16
EP0886647A1 (en) 1998-12-30
HK1021541A1 (en) 2000-06-16
AU709330B2 (en) 1999-08-26
JP2000506837A (ja) 2000-06-06
IL120310A0 (en) 1997-06-10
PL328875A1 (en) 1999-03-01
PT886647E (pt) 2002-12-31
AR006310A1 (es) 1999-08-25
NO983991D0 (no) 1998-08-31
IL120310A (en) 2002-02-10
HUP9900390A2 (hu) 1999-06-28
EP0886647B1 (en) 2002-07-24
WO1997031937A1 (en) 1997-09-04
CZ277898A3 (cs) 1999-06-16
ATE221080T1 (de) 2002-08-15
KR19990087415A (ko) 1999-12-27
TW442452B (en) 2001-06-23
NZ331484A (en) 2000-01-28
DE69714222D1 (de) 2002-08-29
RU2178419C2 (ru) 2002-01-20
ZA971667B (en) 1997-09-10
DK0886647T3 (da) 2002-11-04
US6410684B1 (en) 2002-06-25
TR199801704T2 (xx) 1998-12-21
CA2246246A1 (en) 1997-09-04
BR9707808A (pt) 1999-07-27
CN1212704A (zh) 1999-03-31
HUP9900390A3 (en) 2000-11-28

Similar Documents

Publication Publication Date Title
NO983688L (no) Serin-protease-inhibitorer
NO983991L (no) Serin-protease-inhibitorer
NO983992L (no) Serinprotease inhibitorer
NO992821L (no) Ketobenzamider som calpain-inhibitorer
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BR0011130A (pt) Inibidores de metaloproteases
DK0816376T3 (da) Thrombininhibitorer som antikoagulante midler
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
ID18143A (id) Penghambat metaloprotease amina siklik tersubstitusi
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
NO941937L (no) Sakarinderivater som inhiberer proteolytiske enzymer
TR200101120T2 (tr) Serin proteaz inhibitörü
FI915819A0 (fi) Hiv- proteas-inhibitorer.
DK1142887T3 (da) 5,6-Dihydropyronderivater som proteaseinhibitorer og antivirale midler
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
NO20052487L (no) 1-(4-benzyl-piperazin-1-yl)-3-fenyl-propenonderivater.
NO962018L (no) 5,6-dihydropyron-derivater som protease-inhibitorer og antivirus-midler
FI935780A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
FI935779A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
DK1206444T3 (da) Forbindelser der hæmmer tryptaseaktivitet
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
NO911459D0 (no) Anvendelse av metallion-komplekser som belegginhibitorer.
DE69819539D1 (de) Antithrombotische mittel
NO20044550L (no) Heterotrisyklyl 6-alkaliden-penemer som beta-laktamaseinhibitorer
FI951078A0 (fi) Retrovirusinfektion inhibitio

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application